Figure 4.

MDP enhances the differentiation of Mo-DCs in a mTORC1 independent manner. As described in Figure 3D , human CD14⁺ monocytes were treated or not with MDP, the mTOR activator MHY1485, the PI3K inhibitor wortmannin, or the mTOR inhibitor Rapamycin for 5 days at the same timepoint. Mo-DCs (CD1a⁺) and mo-Macs (CD16⁺) frequencies were assessed by flow cytometry using the HLA-DR, CD16 and CD1a markers. (A) Contour representing the mo-DCs (green) and mo-Macs (purple). (B) The frequency of mo-Macs and mo-DCs in the four conditions are depicted. Representative of 2 experiments with at least 3 biological replicates. Bars indicate mean ± SEM. Statistical significance was assessed by the non-parametric Mann-Whitney test. *P<0.05; **P<0.01.